- Home
- CUE vs CLPR Comparison
CUE vs CLPR Comparison
Compare CUE & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CLPR
- Stock Information
- Founded
- CUE 2014
- CLPR 2015
- Country
- CUE United States
- CLPR United States
- Employees
- CUE N/A
- CLPR N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CLPR Real Estate Investment Trusts
- Sector
- CUE Health Care
- CLPR Real Estate
- Exchange
- CUE Nasdaq
- CLPR Nasdaq
- Market Cap
- CUE 58.9M
- CLPR 57.8M
- IPO Year
- CUE 2018
- CLPR 2017
- Fundamental
- Price
- CUE $0.77
- CLPR $4.07
- Analyst Decision
- CUE Strong Buy
- CLPR
- Analyst Count
- CUE 3
- CLPR 0
- Target Price
- CUE $3.00
- CLPR N/A
- AVG Volume (30 Days)
- CUE 159.5K
- CLPR 87.5K
- Earning Date
- CUE 05-20-2025
- CLPR 05-20-2025
- Dividend Yield
- CUE N/A
- CLPR 9.36%
- EPS Growth
- CUE N/A
- CLPR N/A
- EPS
- CUE N/A
- CLPR N/A
- Revenue
- CUE $9,287,000.00
- CLPR $148,775,000.00
- Revenue This Year
- CUE N/A
- CLPR N/A
- Revenue Next Year
- CUE $25.99
- CLPR N/A
- P/E Ratio
- CUE N/A
- CLPR N/A
- Revenue Growth
- CUE 69.16
- CLPR 7.65
- 52 Week Low
- CUE $0.45
- CLPR $3.38
- 52 Week High
- CUE $2.26
- CLPR $7.12
- Technical
- Relative Strength Index (RSI)
- CUE 44.09
- CLPR 62.22
- Support Level
- CUE $0.71
- CLPR $3.70
- Resistance Level
- CUE $0.78
- CLPR $4.09
- Average True Range (ATR)
- CUE 0.06
- CLPR 0.18
- MACD
- CUE 0.01
- CLPR 0.07
- Stochastic Oscillator
- CUE 38.26
- CLPR 96.25
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.